For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
Inviting an author to review:
Clinicopathological and prognostic features of Epstein-Barr virus infection, microsatellite instability, and PD-L1 expression in gastric cancer.
Find an author and click ‘Invite to review selected article’ near their name.
Search for authorsSearch for similar articles
29
views
44
references
 Top references
cited by
45
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
1 collections
    0
    shares
      0
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found

      PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Key Points

          PET-CT is the modern standard for staging Hodgkin lymphoma and can replace contrast enhanced CT in the vast majority of cases. Agreement between expert and local readers is sufficient for the Deauville criteria to assess response in clinical trials and the community.

          Related collections

          Most cited references44

          • Record: found
          • Abstract: not found
          • Article: not found

          A Coefficient of Agreement for Nominal Scales

          Mitchell Cohen (1960)
          Article 0 comments Cited 2798 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.

            Bruce D Cheson, Richard Fisher, Sally F. Barrington … (2014)
            The purpose of this work was to modernize recommendations for evaluation, staging, and response assessment of patients with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). A workshop was held at the 11th International Conference on Malignant Lymphoma in Lugano, Switzerland, in June 2011, that included leading hematologists, oncologists, radiation oncologists, pathologists, radiologists, and nuclear medicine physicians, representing major international lymphoma clinical trials groups and cancer centers. Clinical and imaging subcommittees presented their conclusions at a subsequent workshop at the 12th International Conference on Malignant Lymphoma, leading to revised criteria for staging and of the International Working Group Guidelines of 2007 for response. As a result, fluorodeoxyglucose (FDG) positron emission tomography (PET)–computed tomography (CT) was formally incorporated into standard staging for FDG-avid lymphomas. A modification of the Ann Arbor descriptive terminology will be used for anatomic distribution of disease extent, but the suffixes A or B for symptoms will only be included for HL. A bone marrow biopsy is no longer indicated for the routine staging of HL and most diffuse large B-cell lymphomas. However, regardless of stage, general practice is to treat patients based on limited (stages I and II, nonbulky) or advanced (stage III or IV) disease, with stage II bulky disease considered as limited or advanced disease based on histology and a number of prognostic factors. PET-CT will be used to assess response in FDG-avid histologies using the 5-point scale. The product of the perpendicular diameters of a single node can be used to identify progressive disease. Routine surveillance scans are discouraged. These recommendations should improve evaluation of patients with lymphoma and enhance the ability to compare outcomes of clinical trials.
            Article 0 comments Cited 1111 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0

              Ronald Boellaard, Roberto Delgado-Bolton, Wim Oyen … (2014)
              The purpose of these guidelines is to assist physicians in recommending, performing, interpreting and reporting the results of FDG PET/CT for oncological imaging of adult patients. PET is a quantitative imaging technique and therefore requires a common quality control (QC)/quality assurance (QA) procedure to maintain the accuracy and precision of quantitation. Repeatability and reproducibility are two essential requirements for any quantitative measurement and/or imaging biomarker. Repeatability relates to the uncertainty in obtaining the same result in the same patient when he or she is examined more than once on the same system. However, imaging biomarkers should also have adequate reproducibility, i.e. the ability to yield the same result in the same patient when that patient is examined on different systems and at different imaging sites. Adequate repeatability and reproducibility are essential for the clinical management of patients and the use of FDG PET/CT within multicentre trials. A common standardised imaging procedure will help promote the appropriate use of FDG PET/CT imaging and increase the value of publications and, therefore, their contribution to evidence-based medicine. Moreover, consistency in numerical values between platforms and institutes that acquire the data will potentially enhance the role of semiquantitative and quantitative image interpretation. Precision and accuracy are additionally important as FDG PET/CT is used to evaluate tumour response as well as for diagnosis, prognosis and staging. Therefore both the previous and these new guidelines specifically aim to achieve standardised uptake value harmonisation in multicentre settings.
              Article 0 comments Cited 611 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Journal
                Title: Blood
                Publisher: American Society of Hematology
                ISSN (Print): 0006-4971
                ISSN (Electronic): 1528-0020
                Publication date Created: March 24 2016
                Publication date (Print): March 24 2016
                Volume: 127
                Issue: 12
                Pages: 1531-1538
                Affiliations
                [1 ]PET Imaging Centre, Division of Imaging Sciences and Biomedical Engineering, King’s College London, King’s Health Partners, St. Thomas’ Hospital, London, United Kingdom;
                [2 ]Cancer Research UK and UCL Cancer Trials Centre, London, United Kingdom;
                [3 ]Department of Nuclear Medicine, University of Modena and Reggio Emilia, Modena, Italy;
                [4 ]Department of Molecular Imaging (PET-CT), Royal Prince Alfred Hospital, Sydney, Australia;
                [5 ]Sydney Medical School, University of Sydney, Sydney, Australia;
                [6 ]Department of Medical Imaging and Physiology and
                [7 ]Department of Oncology and Radiation Physics, Skane University Hospital, Lund University, Lund, Sweden;
                [8 ]Department of Nuclear Medicine & PET Centre, Aarhus University Hospital, Aarhus, Denmark;
                [9 ]Department of Radiology, Guy's and St. Thomas' National Health Service (NHS) Foundation Trust, London, United Kingdom;
                [10 ]Oncology Unit, Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy;
                [11 ]The University of Manchester and the Christie NHS Foundation Trust, Manchester, United Kingdom;
                [12 ]Concord, Repatriation General Hospital, Sydney, Australia;
                [13 ]Department of Oncology, Norwegian Radium Hospital, Oslo, Norway;
                [14 ]Haematology, Auckland City Hospital, Auckland, New Zealand;
                [15 ]Department of Genetics and Pathology, Experimental and Clinical Oncology, Uppsala University, Uppsala, Sweden;
                [16 ]Haematology, Aarhus University, Aarhus, Denmark; and
                [17 ]Cancer Research UK Centre, University of Southampton, Southampton, United Kingdom
                Article
                DOI: 10.1182/blood-2015-11-679407
                PubMed ID: 26747247
                SO-VID: faa1d74a-0238-4411-8f14-4ab6abf86804
                Copyright © © 2016
                History

                Data availability:

                Comments

                Comment on this article

                scite_

                Cited by45

                See all cited by

                Most referenced authors763

                See all reference authors